Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer

Lung Cancer

Volumn 74, Issue 1, 2011, Pages 85-88

  Shiroyama, Takayuki ^a   Komuta, Kiyoshi ^a   Imamura, Fumio ^b   Hirashima, Tomonori ^c   Kijima, Takashi ^d   Tachibana, Isao ^d   Kawase, Ichiro ^d  

^a OSAKA POLICE HOSPITAL   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Ambulatory setting; Lung cancer; Oral medication; Platinum refractory; S 1 monotherapy; Second line

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PLATINUM COMPOUNDS; RECURRENCE; TEGAFUR; TREATMENT OUTCOME;

EID: 80052587586     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.017     Document Type: Article

References (29)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
2. Stephens R., Fairlamb D., Gower N., Maslove L., Milroy R., Napp V., et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC): preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 2002, 21:291a. (abstr 1161).
3. Chemotherapy in non-small cell lung cancer-a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995, 311:899-909. Non-Small Cell Lung Cancer Collaborative Group.
4. Grilli R., Oxman A., Julian J. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough?. J Clin Oncol 1993, 11:1866-1872.
5. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
6. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354-2362.
7. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer to gefitinib. Lancet 2008, 372:1809-1818.
8. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Eng J Med 2005, 353:123-132.
9. Maruyama R., Nishiwaki Y., Tamura T., Yamamoto N., Tsuboi M., Nakagawa K., et al. Phase III study V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008, 26:4244-4252.
10. Ohe Y., Ichinose Y., Nakagawa K., Tamura T., Kubota K., Yamamoto N., et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008, 14:4206-4212.
11. Di Maio M., Chiodini P., Georqoulias V., Hatzidaki D., Takeda K., Wachters F.M., et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:1836-1843.
12. Shirasaka T., Shimamoto Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., et al. Development of a novel form of 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor-selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7:548-557.
13. Sugimachi K., Maehara Y., Horikoshi N., Shimada Y., Sakata Y., Mitachi Y., et al. An early phase II study of oral S-1 a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999, 57:202-210.
14. Koizumi W., Kurihara M., Nakano S., Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil in advanced gastric cancer. Oncology 2000, 58:191-197.
15. Ohtsu A., Baba H., Sakata Y., Mitachi Y., Horikoshi N., Sugimachi K., et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 2000, 83:141-145.
16. Inuyama M., Kida A., Tsukuda M., Kohno N., Satake B. Early phase II study of S-1 in patients with advanced head and neck cancer. Jpn J Cancer Chemother 1998, 25:1151-1158.
17. Inuyama M., Kida A., Tsukuda M., Kohno N., Satake B. Late phase II study of S-1 in patients with advanced head and neck cancer. Jpn J Cancer Chemother 2001, 28:1381-1390.
18. Saeki T., Takashima S., Sano M., Horikoshi N., Miura S., Shimizu S., et al. A phase II study of S-1 in patients with metastatic breast cancer-A Japanese Trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 2004, 11:194-202.
19. Saeki T., Takashima S., Sano M., Horikoshi N., Miura S., Shimizu S., et al. A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer. Jpn J Cancer Chemother 2004, 31:539-547.
20. Ueno H., Okusaka T., Ikeda M., Takezako Y., Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005, 68:171-178.
21. Ueno H., Okusaka T., Ikeda M., Takezako Y., Morizane Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004, 91:1769-1774.
22. Kawahara M., Furuse K., Segawa Y., Yoshimori K., Matsui K., Kudoh S., et al. Phase II study of S-1 a novel oral fluorouracil in advanced non-small-cell lung cancer. Br J Cancer 2001, 85:939-943.
23. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
24. Scagliotti G.V., Parkih P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
25. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 2009, 361:947-957.
26. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin docetaxel in patients with non-small lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010, 11:121-128.
27. Massarelli E., Andre F., Liu D.D., Lee J.J., Wolf M., Fandi A., et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003, 39:55-61.
28. Totani Y., Saito Y., Hayashi M., Tada T., Kohashi Y., Mieno Y., et al. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2009, 64:1181-1185.
29. Yamamoto N., Yamanaka T., Ichinose Y., Kubota K., Sakai H., Genma A., et al. Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type. Anticancer Res 2010, 30:2985-2990.